Contact Us
18 Dec 2025
Go Back

Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine

Share this:

Human challenge trials evaluate protection from influenza exposure following vaccination but have not been reported for nucleoside-modified messenger ribonucleic acid (modRNA) influenza vaccines.

Other recent posts

If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.

Contact hVIVO

Stay connected

Sign up to our emails and follow us on social media to keep up to date with hVIVO.

By clicking Sign Up you're confirming that you agree with our Privacy Policy.
chevron-downarrow-up